Détail d'une personne de l'annuaire - fr | Cancéropôle Est, la recherche innovante dans la lutte contre le cancer

18 conférence francophone d'épidémiologie clinique et 31 journées des statisticiens des centres de lutte contre le cancer.

Binquet C, Bertaut A

J Epidemiol Popul Health. 2024 04 6;72 Suppl 2:202521

Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

Roussot N, Constantin G, Desmoulins I, Bergeron A, Arnould L, Beltjens F, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Jacinto S, Michel E, Amet A, Coutant C, Costa B, Jouannaud C, Deblock M, Levy C, Ferrero JM, Kerbrat P, Brain E, Mouret-Reynier MA, Coudert B, Bertaut A, Ladoire S

Eur J Cancer. 2024 03 26;202:114037

ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial.

Zilli T, Franzese C, Guckenberger M, Giaj-Levra N, Mach N, Koutsouvelis N, Achard V, McDonald A, Alongi F, Scorsetti M, Constantin G, Bertaut A, Miralbell R

Radiother Oncol. 2024 02 23;:110181

Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research.

Guérin J, Nahid A, Tassy L, Deloger M, Bocquet F, Thézenas S, Desandes E, Le Deley MC, Durando X, Jaffré A, Es-Saad I, Crochet H, Le Morvan M, Lion F, Raimbourg J, Khay O, Craynest F, Giro A, Laizet Y, Bertaut A, Joly F, Livartowski A, Heudel P

Int J Environ Res Public Health. 2024 02 7;21(2):

Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.

Ilie SM, Briot N, Constatin G, Ilie A, Beltjens F, Ladoire S, Desmoulins I, Hennequin A, Bertaut A, Coutant C, Causeret S, Ghozali N, Coudert B, Arnould L

Front Oncol. 2024 01 10;13:1309890

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.

Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C

BMC Cancer. 2023 11 9;23(1):1080

Patient satisfaction, experience and preferences in the implementation of genetics teleconsultations in the North-eastern region of France.

Lançon A, Beaudouin A, Lambert L, Baurand A, Petit E, Schaefer E, Poirsier C, Piard J, Patay L, Garde A, Bournez M, Bertolone G, Kastner C, Tempé L, El Chehadeh S, Spodenkiewick M, Lissy L, Doco-Fenzy M, Cabrol C, Trouvé C, Brischoux EB, Cloteau M, Burtin A, Renaud M, Riviere A, Quentin T, De Souza CS, Sawka C, Racine C, Robert M, Gautier E, Delanne J, Bertaut A, Thauvin-Robinet C, Faivre L, Nambot S

Eur J Med Genet. 2023 09 13;:104841

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.

Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F

Nat Med. 2023 08 10;:

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Bergeron A, Arnould L, Beltjens F, Desmoulin I, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Amet A, Coutant C, Coudert B, Bertaut A, Ladoire S

Breast Cancer. 2023 08 10;:

Impact of Covid-19 on breast cancer stage at discovery, and time to treatment in Cote d'Or, France.

Feron Agbo C, Assogba E, Bertaut A, Mamguem Kamga A, Coutant C, Desmoulins I, Dancourt V, Sandrine Dabakuyo Yonli T

Prev Med Rep. 2023 08;34:102248

Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.

Balazard F, Bertaut A, Bordet É, Mulard S, Blanc J, Briot N, Paux G, Dhaini Merimeche A, Rigal O, Coutant C, Fournier M, Jouannaud C, Soulie P, Lerebours F, Cottu PH, Tredan O, Vanlemmens L, Levy C, Mouret-Reynier MA, Campone M, Brady KJS, Sasane M, Rice M, Coulouvrat C, Martin AL, Jacquet A, Vaz-Luis I, Herold C, Pistilli B

J Natl Cancer Inst. 2023 07 12;:

Associated Factors to Efficacy and Tolerance of Immunotherapy in Older Patients with Cancer Aged 70 Years and Over: Impact of Coprescriptions.

Perret M, Bertaut A, Niogret J, Marilier S, Jouanny P, Manckoundia P, Bengrine-Lefevre L, Quipourt V, Barben J

Drugs Aging. 2023 07 10;:

Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers.

Bergeron A, Bertaut A, Beltjens F, Charon-Barra C, Amet A, Jankowski C, Desmoulins I, Ladoire S, Arnould L

Br J Cancer. 2023 04 29;:

Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.

Piquemal D, Bruno R, Bournet B, Ghiringhelli F, Noguier F, Canivet C, Bertaut A, Pierrat F, Evesque L, Gamez A, Cros J, Rederstorff E, Petit E, Adnet J, Saint A, Drouillard A, Kempf E, Soularue E, Vincent J, Baumgaertner I, Hennequin A, Tournigand C, Lopez Trabada Ataz D, Bengrine L, Lepage C, Manfredi S, Afchain P, Trouilloud I, Gagnaire A, LoConte NK, Bachet JB

J Gastrointest Oncol. 2023 04 29;14(2):997-1007

Performance of [18F]FDG-PET/CT Imaging in First Recurrence of Invasive Lobular Carcinoma.

Bonnin D, Ladoire S, Briot N, Bertaut A, Drouet C, Cochet A, Alberini JL

J Clin Med. 2023 04 17;12(8):

Every-other-day vs once-a-week urethra-sparing prostate SBRT: 5-year results of a randomized phase II trial.

Zilli T, Jorcano S, Bral S, Symon Z, Rubio C, Bruynzeel A, Ibrahimov R, Minn H, Oliveira A, Bertaut A, Constantin G, Miralbell R

Int J Radiat Oncol Biol Phys. 2023 03 29;:

Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.

Courtinard C, Gourgou S, Jacot W, Carton M, Guérin O, Vacher L, Bertaut A, Le Deley MC, Pérol D, Marino P, Levy C, Uwer L, Perrocheau G, Schiappa R, Bachelot F, Parent D, Breton M, Petit T, Filleron T, Loeb A, Pélissier SM, Robain M, Delaloge S, Bellera C

BMC Med. 2023 03 8;21(1):87

Prognostic factors and outcomes of adult spermatic cord sarcoma. A study from the French Sarcoma Group.

Achard G, Charon-Barra C, Carrere S, Bonvalot S, Meeus P, Fau M, Honoré C, Delhorme JB, Tzanis D, Le Loarer F, Karanian-Philippe M, Ngo C, Le Guellec S, Bertaut A, Causeret S, Isambert N

Eur J Surg Oncol. 2023 02 26;:

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.

Réda M, Fouquier A, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Coudert B, Bertaut A, Ladoire S

Breast. 2023 02 4;68:149-156

Prediction of prostate cancer recurrence after radiation therapy using multiparametric magnetic resonance imaging and spectroscopy: assessment of prognostic factors on pretreatment imaging.

Asuncion A, Walker PM, Bertaut A, Blanc J, Labarre M, Martin E, Bardet F, Cassin J, Cormier L, Crehange G, Loffroy R, Cochet A

Quant Imaging Med Surg. 2022 12;12(12):5309-5325

Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort.

Tankere P, Boidot R, Bonniaud P, Zouak A, Foucher P, Milliere A, Bertaut A, Favier L, Lagrange A, Ghiringhelli F, Kaderbhai CG, Fraisse C

J Thorac Dis. 2022 06;14(6):2034-2044

Treatment related factors associated with the risk of breast radio-induced-sarcoma.

Mirjolet C, Diallo I, Bertaut A, Veres C, Sargos P, Helfre S, Sunyach MP, Truc G, Le Pechoux C, Paumier A, Ducassou A, Jolnerovski M, Thariat J, Lapeyre M, Cordoba A, Mahé MA, Maingon P

Radiother Oncol. 2022 Apr 8;:

Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.

Edeline J, Hirano S, Bertaut A, Konishi M, Benabdelghani M, Uesaka K, Watelet J, Ohtsuka M, Hammel P, Kaneoka Y, Joly JP, Yamamoto M, Monard L, Ambo Y, Louvet C, Ando M, Malka D, Nagino M, Phelip JM, Ebata T

Eur J Cancer. 2022 Feb 16;164:80-87

Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.

Ladoire S, Rederstorff E, Goussot V, Parnalland S, Briot N, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F

Eur J Cancer. 2022 Feb 1;165:13-24

OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.

Vachenc S, Gobbo J, Moujarrebe SE, Desmoulins I, Gilabert M, Beau-Faller M, Mitry E, Girard N, Bertaut A, Dusetti N, Iovanna JL, Yousfi R, Pierrat F, Bruno R, Cueff A, Boidot R, Genne P

BMC Cancer. 2022 Jan 6;22(1):41

Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.

Costaz H, Boulle D, Bertaut A, Rouffiac M, Beltjens F, Desmoulins I, Peignaux K, Ladoire S, Causeret S, Loustalot C, Padeano MM, Vincent L, Jankowski C, Arnould L, Coutant C

Bull Cancer. 2021 Nov 24;:

Exclusive Chemoradiotherapy With or Without Radiation Dose Escalation in Esophageal Cancer: Multicenter Phase 2/3 Randomized Trial CONCORDE (PRODIGE-26).

Crehange G, M'vondo C, Bertaut A, Pereira R, Rio E, Peiffert D, Gnep K, Benezery K, Ronchin P, Noel G, Mineur L, Drouillard A, Blanc J, Rouffiac M, Boustani J

Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S5

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer.

Bellio H, Bertaut A, Hervieu A, Zanetta S, Hennequin A, Vincent J, Palmier R, Bengrine-Lefevre L, Ghiringhelli F, Fumet JD

Cancers (Basel). 2021 Oct 30;13(21):

Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study.

Bertaut A, Touchefeu Y, Blanc J, Bouché O, François E, Conroy T, Artru P, Adenis A, Gobbo J, Borg C, Ghiringhelli F, Bennouna J

Clin Colorectal Cancer. 2021 Oct 3;:

Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue.

Lapidari P, Djehal N, Havas J, Gbenou A, Martin E, Charles C, Dauchy S, Pistilli B, Cadeau C, Bertaut A, Everhard S, Martin AL, Coutant C, Cottu P, Menvielle G, Dumas A, Andre F, Michiels S, Vaz-Luis I, Di Meglio A

Breast Cancer Res Treat. 2021 Sep 24;:

Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer.

Tharin Z, Blanc J, Alaoui IC, Bertaut A, Ghiringhelli F

J Gastrointest Oncol. 2021 Aug;12(4):1509-1517

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.

Bergeron A, MacGrogan G, Bertaut A, Ladoire S, Arveux P, Desmoulins I, Bonnefoi H, Loustalot C, Auriol S, Beltjens F, Degrolard-Courcet E, Charon-Barra C, Richard C, Boidot R, Arnould L

Mod Pathol. 2021 Mar 22;:

Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.

Ladoire S, Goussot V, Redersdorff E, Cueff A, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hanu R, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F

Eur J Cancer. 2021 Feb 27;148:359-370

ER-/PR+ breast cancer: a distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.

Beltjens F, Molly D, Bertaut A, Richard C, Desmoulins I, Loustalot C, Charon-Barra C, Courcet E, Bergeron A, Ladoire S, Jankowski C, Boidot R, Arnould L

Int J Cancer. 2021 Feb 26;:

Glassy cell carcinoma of the uterine cervix: 20-year experience from a comprehensive cancer center.

Boustani J, Achkar S, Bertaut A, Genestie C, Gouy S, Pautier P, Morice P, Haie-Meder C, Chargari C

Cancer Radiother. 2021 Jan 3;:

Influence of primary tumor location and resection on survival in metastatic colorectal cancer.

Tharin Z, Blanc J, Alaoui IC, Bertaut A, Ghiringhelli F

World J Gastrointest Oncol. 2020 Nov 15;12(11):1296-1310

[Multidisciplinary team meeting in supportive care: 12 years of experience in a French comprehensive cancer center].

Favier L, Bremaud N, Tharin Z, Blanc J, Bertaut A, Alavoine V, Dubief A, Truc G, Dorlean C, Coudert B

Bull Cancer. 2020 Sep 21;:

Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer.

Boustani J, Derangère V, Bertaut A, Adotevi O, Morgand V, Charon-Barra C, Ghiringhelli F, Mirjolet C

Cells. 2020 Sep 10;9(9):

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable a

Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F

BMC Cancer. 2020 Aug 10;20(1):748

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.

Niogret J, Limagne E, Thibaudin M, Blanc J, Bertaut A, Le Malicot K, Rinaldi Y, Caroli-Bosc FX, Audemar F, Nguyen S, Sarda C, Lombard-Bohas C, Locher C, Carreiro M, Legoux JL, Etienne PL, Baconnier M, Porneuf M, Aparicio T, Ghiringhelli F

Cancers (Basel). 2020 May 31;12(6):

Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer.

Kaderbhaï CG, Coudert B, Bertaut A, Adnet J, Favier L, Lagrange A, Peignaux-Casasnovas K, Mettey L, Tharin Z, Foucher P, Martin E

Cancer Radiother. 2020 May 18;:

Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation.

Mengue L, Bertaut A, Ngo Mbus L, Doré M, Ayadi M, Clément-Colmou K, Claude L, Carrie C, Laude C, Tanguy R, Blanc J, Sunyach MP

Radiat Oncol. 2020 Apr 17;15(1):82

Evaluation of the quality of the information received during head and neck cancer announcement: Prospective two-center study.

Thibouw F, Duvillard C, Thibouw D, Bertaut A, Blanc J, Vulquin N, Chevalier C, Guigou C, Folia M

Head Neck. 2020 Feb 24;:

Implementation and use of whole exome sequencing in daily practice for metastatic solid cancer.

Réda M, Richard C, Bertaut A, Niogret J, Collot T, Fumet JD, Blanc J, Truntzer C, Desmoulins I, Ladoire S, Hennequin A, Favier L, Bengrine L, Vincent J, Hervieu A, Dusserre JG, Lepage C, Foucher P, Borg C, Albuisson J, Arnould L, Nambot S, Faivre L, Boidot R, Ghiringhelli F

EBioMedicine. 2020 Jan 7;51:102624

Membrane-bound exosomal HSP70 as a biomarker for detection and monitoring of malignant solid tumours: a pilot study.

Chanteloup G, Cordonnier M, Isambert N, Bertaut A, Marcion G, Garrido C, Gobbo J

Pilot Feasibility Stud. 2020 ;6:35

Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study.

Chanteloup G, Cordonnier M, Isambert N, Bertaut A, Hervieu A, Hennequin A, Luu M, Zanetta S, Coudert B, Bengrine L, Desmoulins I, Favier L, Lagrange A, Pages PB, Gutierrez I, Lherminier J, Avoscan L, Jankowski C, Rébé C, Chevriaux A, Padeano MM, Coutant C, Ladoire S, Causeret S, Arnould L, Charon-Barra C, Cottet V, Blanc J, Binquet C, Bardou M, Garrido C, Gobbo J

J Extracell Vesicles. 2020 ;9(1):1766192

Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial.

Zilli T, Franzese C, Bottero M, Giaj-Levra N, Förster R, Zwahlen D, Koutsouvelis N, Bertaut A, Blanc J, Roberto D'agostino G, Alongi F, Guckenberger M, Scorsetti M, Miralbell R

Radiother Oncol. 2019 Aug 17;:

Visceral osteopathic manipulative treatment reduces patient reported digestive toxicities induced by adjuvant chemotherapy in breast cancer: A randomized controlled clinical study.

Lagrange A, Decoux D, Briot N, Hennequin A, Coudert B, Desmoulins I, Bertaut A

Eur. J. Obstet. Gynecol. Reprod. Biol.. 2019 Aug 12;241:49-55

Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.

Ghiringhelli F, Vincent J, Bengrine L, Borg C, Jouve JL, Loffroy R, Guiu B, Blanc J, Bertaut A

J. Cancer Res. Clin. Oncol.. 2019 Jul 4;:

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.

Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet JD, Crehange G, Ghiringhelli F, Mirjolet C

J Immunother Cancer. 2019 Jun 25;7(1):160

RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study.

Mirjolet C, Merlin JL, Truc G, Noël G, Thariat J, Domont J, Sargos P, Renard-Oldrini S, Ray-Coquard I, Liem X, Chevreau C, Lagrange JL, Mahé MA, Collin F, Bonnetain F, Bertaut A, Maingon P

EBioMedicine. 2019 Feb 28;:

Limbs and trunk soft tissue sarcoma systematic local and remote monitoring by MRI and thoraco-abdomino-pelvic scanner: A single-centre retrospective study.

De Angelis F, Guy F, Méjean N, Varbedian O, Bertaut A, Isambert N, Hervieu A, Truc G, Thibouw D, Barra CC, Fraisse J, Burnier P, Causeret S

Eur J Surg Oncol. 2019 Feb 5;:

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, Boudjema K, Fartoux L, Bouhier-Leporrier K, Jouve JL, Faroux R, Guerin-Meyer V, Kurtz JE, Assénat E, Seitz JF, Baumgaertner I, Tougeron D, de la Fouchardière C, Lombard-Bohas C, Boucher E, Stanbury T, Louvet C, Malka D, Phelip JM

J. Clin. Oncol.. 2019 Feb 1;:JCO1800050

Patterns of Bone Failure in Localized Prostate Cancer Previously Irradiated: The Preventive Role of External Radiotherapy on Pelvic Bone Metastases.

Grapin M, Quivrin M, Bertaut A, Martin E, Cormier L, Ladoire S, Cochet A, Créhange G

Front Oncol. 2019 ;9:70

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.

Bennouna J, Hiret S, Bertaut A, Bouché O, Deplanque G, Borel C, François E, Conroy T, Ghiringhelli F, des Guetz G, Seitz JF, Artru P, Hebbar M, Stanbury T, Denis MG, Adenis A, Borg C

JAMA Oncol. 2018 Oct 25;:

Salvage extended field or involved field nodal irradiation in F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer.

Lépinoy A, Silva YE, Martin E, Bertaut A, Quivrin M, Aubignac L, Cochet A, Créhange G

Eur. J. Nucl. Med. Mol. Imaging. 2018 Sep 28;:

ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial.

Zilli T, Scorsetti M, Zwahlen D, Franzese C, Förster R, Giaj-Levra N, Koustouvelis N, Bertaut A, Zimmermann M, D'Agostino GR, Alongi F, Guckenberger M, Miralbell R

Radiat Oncol. 2018 Sep 4;13(1):166

Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy.

Thibouw D, Truc G, Bertaut A, Chevalier C, Aubignac L, Mirjolet C

J. Neurooncol.. 2018 Apr;137(2):429-438

Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial.

Fumet JD, Bertaut A, Bengrine L, Lapierre P, Vincent J, Ghiringhelli F, Falvo N

Oncotarget. 2018 Feb 27;9(16):12599-12608

5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer.

Morawska K, Goirand F, Marceau L, Devaux M, Cueff A, Bertaut A, Vincent J, Bengrine-Lefevre L, Ghiringhelli F, Schmitt A

Oncotarget. 2018 Feb 20;9(14):11559-11571

Pattern of breast cancer blood flow and metabolism, assessed using dual-acquisition FDG PET: correlation with tumor phenotypic features and pathological response to neoadjuvant chemotherapy.

Humbert O, Lasserre M, Bertaut A, Fumoleau P, Coutant C, Brunotte F, Cochet A

J. Nucl. Med.. 2018 Feb 9;:

Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries.

Cortet M, Bertaut A, Molinié F, Bara S, Beltjens F, Coutant C, Arveux P

BMC Cancer. 2018 02 7;18(1):161

Does mammogram attendance influence participation in cervical and colorectal cancer screening? A prospective study among 1856 French women.

Bertaut A, Coudert J, Bengrine L, Dancourt V, Binquet C, Douvier S

PLoS ONE. 2018 ;13(6):e0198939

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.

Depardon E, Kanoun S, Humbert O, Bertaut A, Riedinger JM, Tal I, Vrigneaud JM, Lasserre M, Toubeau M, Berriolo-Riedinger A, Dygai-Cochet I, Fumoleau P, Brunotte F, Cochet A

PLoS ONE. 2018 ;13(7):e0199529

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study.

Isambert N, Hervieu A, Rébé C, Hennequin A, Borg C, Zanetta S, Chevriaux A, Richard C, Derangère V, Limagne E, Blanc J, Bertaut A, Ghiringhelli F

Oncoimmunology. 2018 ;7(9):e1474319

Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience.

Reynaud T, Bertaut A, Farah W, Thibouw D, Crehange G, Truc G, Vulquin N

Technol. Cancer Res. Treat.. 2018 Jan 1;17:1533033818806498

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.

Fumet JD, Isambert N, Hervieu A, Zanetta S, Guion JF, Hennequin A, Rederstorff E, Bertaut A, Ghiringhelli F

ESMO Open. 2018 ;3(4):e000375

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study.

Mirjolet C, Charon-Barra C, Ladoire S, Arbez-Gindre F, Bertaut A, Ghiringhelli F, Leroux A, Peiffert D, Borg C, Bosset JF, Créhange G

Oncoimmunology. 2018 ;7(3):e1396402

Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.

Augustin A, Le Gouill S, Gressin R, Bertaut A, Monnereau A, Woronoff AS, Trétarre B, Delafosse P, Troussard X, Moreau A, Hermine O, Maynadié M

J. Cancer Res. Clin. Oncol.. 2017 Oct;:

Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC, Chowdhury S, Niegisch G, Yu EY, Pal SK, De Giorgi U, Crabb SJ, Caubet M, Balssa L, Milowsky MI, Ladoire S, Créhange G,

Acta Oncol. 2017 Aug;:1-7

Safety and efficacy of transcatheter embolization with Glubran(®)2 cyanoacrylate glue for acute arterial bleeding: a single-center experience with 104 patients.

Abdulmalak G, Chevallier O, Falvo N, Di Marco L, Bertaut A, Moulin B, Abi-Khalil C, Gehin S, Charles PE, Latournerie M, Midulla M, Loffroy R

Abdom Radiol (NY). 2017 Aug;:

Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study.

Marshall EM, Bertaut A, Desmoulins I, Darut-Jouve A, Ponnelle T, Poillot ML, Beltjens F, Arveux P

Breast J. 2017 Mar;23(2):138-145

Selective arterial embolization of symptomatic and asymptomatic renal angiomyolipomas: a retrospective study of safety, outcomes and tumor size reduction.

Bardin F, Chevallier O, Bertaut A, Delorme E, Moulin M, Pottecher P, Di Marco L, Gehin S, Mourey E, Cormier L, Mousson C, Midulla M, Loffroy R

Quant Imaging Med Surg. 2017 Feb;7(1):8-23

Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study.

Auguste A, Cortet M, Dabakuyo-Yonli TS, Launay L, Arnould L, Desmoulins I, Roignot P, Darut-Jouve A, Poillot ML, Bertaut A, Arveux P

PLoS ONE. 2017 ;12(2):e0170069

Immune classifications with cytotoxic CD8(+) and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.

Madkouri R, Kaderbhai CG, Bertaut A, Truntzer C, Vincent J, Aubriot-Lorton MH, Farah W, Limagne E, Ladoire S, Boidot R, Derangère V, Ghiringhelli F

Oncoimmunology. 2017 ;6(6):e1321186

Impact of waiting time on nodal staging in head and neck squamous-cell carcinoma treated with radical intensity modulated radiotherapy.

Chevalier C, Bertaut A, Quivrin M, Vulquin N, Desandes C, Folia M, Duvillard C, Truc G, Crehange G, Maingon P

Clin Transl Radiat Oncol. 2016 Dec;1:27-32

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.

Guion-Dusserre JF, Bertaut A, Ghiringhelli F, Vincent J, Quipourt V, Marilier S, Tharin Z, Bengrine-Lefevre L

World J. Gastroenterol.. 2016 Nov;22(42):9378-9386

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.

Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangère V, Vincent J, Chauffert B, Aubriot-Lorton MH, Farah W, Mourier KL, Boidot R, Ghiringhelli F

Oncotarget. 2016 Oct;7(43):70948-70958

Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer.

Gobbo J, Marcion G, Cordonnier M, Dias AM, Pernet N, Hammann A, Richaud S, Mjahed H, Isambert N, Clausse V, Rébé C, Bertaut A, Goussot V, Lirussi F, Ghiringhelli F, de Thonel A, Fumoleau P, Seigneuric R, Garrido C

J. Natl. Cancer Inst.. 2016 Mar;108(3):